<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04302454</url>
  </required_header>
  <id_info>
    <org_study_id>RT2019-13</org_study_id>
    <nct_id>NCT04302454</nct_id>
  </id_info>
  <brief_title>Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy</brief_title>
  <acronym>ADOPT</acronym>
  <official_title>Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this project is to test the hypothesis that the addition of ADT to
      metastasis-directed radiotherapy (MDRT) in well-selected PCa patients with oligo-metastatic
      disease prolongs the metastases progression-free survival (MPFS) compared to MDRT alone.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicentre, randomized study. A total of 280 patients will participate in this study, equally divided between both study groups</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metastases progression-free survival (MPFS)</measure>
    <time_frame>2.5 years after treatment</time_frame>
    <description>The primary aim of this project is to test the hypothesis that the addition of ADT to MDRT in well-selected PCa patients with oligo-metastatic disease (OM) prolongs the metastases progression-free survival (MPFS) compared to MDRT alone</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiotherapy without hormonal therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherpay combined with hormonal therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiotherapy</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuproreline</intervention_name>
    <description>Hormonal therapy</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Histologically proven initial diagnosis of adenocarcinoma of the Prostate.

          2. Biochemical recurrence of prostate cancer following primary local prostate treatment
             (radical prostatectomy, primary radiotherapy or radical prostatectomy +/- prostate bed
             adjuvant salvage radiotherapy) according to the EAU guidelines 2018. BCR after
             surgery: PSA &gt; 0.1ng/ml. BCR after radiotherapy: PSA nadir +2 ng/ml or 3 consequent
             rises in PSA level (after exclusion of possible bounce effect).

          3. Minimal 1 lesion and maximum 4 lesions (bone + lymph nodes) in total, without evidence
             of visceral metastases.

               1. Nodal relapse (N1) in the pelvis on PSMA-PET/CT with a maximum of 4 positive
                  lymph nodes. The upper limit of the pelvis is defined as the aortic bifurcation.

               2. Nodal relapse (M1a) on PSMA-PET/CT above the aortic bifurcation with a maximum of
                  3 positive lymph nodes.

               3. Bone relapse on PSMA-PET/CT with a maximum of 3 lesions.

               4. Combination of a, b, c with a maximum of 4 metastases.

          4. Age &gt; 18 years.

          5. Recent PSMA-PET/CT scan within 60 days prior to randomization.

          6. PSA &lt; 10 ng/ml.

          7. In case of chronic use of finasteride the PSA value should be &lt; 5 ng/ml.

          8. WHO performance state 0-2.

          9. Signed informed consent prior to registration/randomization.

        Exclusion criteria

          1. Visceral metastases.

          2. PSA ≥ 10 ng/ml.

          3. PSA-doubling time ≤ 3 months.

          4. ADT or chemotherapy for recurrent PCa.

          5. Testosterone &lt; 1.7 nmol/l

          6. Painful metastases needed pain medication (&gt; level 1 pain medication) .

          7. Invasive active cancers other than superficial non-melanoma skin cancers.

          8. Inability or unwillingness to understand the information on trial-related topics, to
             give informed consent or to fill out QoL questionnaires.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. Al-Uwini, dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jorinde Janssen, drs.</last_name>
    <phone>0031631623127</phone>
    <email>j.janssen02@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>P. Veldhuijzen van Zanten</last_name>
    <phone>0031503614659</phone>
    <email>adopt@rt.umcg.nl</email>
  </overall_contact_backup>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Shafak Al-Uwini</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

